Literature DB >> 10903733

TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase.

A Hatzoglou1, J Roussel, M F Bourgeade, E Rogier, C Madry, J Inoue, O Devergne, A Tsapis.   

Abstract

BCMA (B cell maturation) is a nonglycosylated integral membrane type I protein that is preferentially expressed in mature B lymphocytes. Previously, we reported in a human malignant myeloma cell line that BCMA is not primarily present on the cell surface but lies in a perinuclear structure that partially overlaps the Golgi apparatus. We now show that in transiently or stably transfected cells, BCMA is located on the cell surface, as well as in a perinulear Golgi-like structure. We also show that overexpression of BCMA in 293 cells activates NF-kappa B, Elk-1, the c-Jun N-terminal kinase, and the p38 mitogen-activated protein kinase. Coimmunoprecipitation experiments performed in transfected cells showed that BCMA associates with TNFR-associated factor (TRAF) 1, TRAF2, and TRAF3 adaptor proteins. Analysis of deletion mutants of the intracytoplasmic tail of BCMA showed that the 25-aa protein segment, from position 119 to 143, conserved between mouse and human BCMA, is essential for its association with the TRAFs and the activation of NF-kappa B, Elk-1, and c-Jun N-terminal kinase. BCMA belongs structurally to the TNFR family. Its unique TNFR motif corresponds to a variant motif present in the fourth repeat of the TNFRI molecule. This study confirms that BCMA is a functional member of the TNFR superfamily. Furthermore, as BCMA is lacking a "death domain" and its overexpression activates NF-kappa B and c-Jun N-terminal kinase, we can reasonably hypothesize that upon binding of its corresponding ligand BCMA transduces signals for cell survival and proliferation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10903733     DOI: 10.4049/jimmunol.165.3.1322

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  74 in total

1.  B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses.

Authors:  S Xu; K P Lam
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

2.  Functional expression of a proliferation-related ligand in hepatocellular carcinoma and its implications for neovascularization.

Authors:  Hiroshi Okano; Katsuya Shiraki; Yutaka Yamanaka; Hidekazu Inoue; Tomoyuki Kawakita; Yukiko Saitou; Yumi Yamaguchi; Naoyuki Enokimura; Keiichi Ito; Norihiko Yamamoto; Kazushi Sugimoto; Kazumoto Murata; Takeshi Nakano
Journal:  World J Gastroenterol       Date:  2005-08-14       Impact factor: 5.742

3.  Response to TNF-α Is Increasing Along with the Progression in Barrett's Esophagus.

Authors:  Olga Chemnitzer; Katharina Götzel; Luisa Maurer; Arne Dietrich; Uwe Eichfeld; Orestis Lyros; Boris Jansen-Winkeln; Albrecht Hoffmeister; Ines Gockel; René Thieme
Journal:  Dig Dis Sci       Date:  2017-10-30       Impact factor: 3.199

4.  B-cell activating factor-receptor specific activation of tumor necrosis factor receptor associated factor 6 and the phosphatidyl inositol 3-kinase pathway in lymphoma B cells.

Authors:  Frank Secreto; Michelle Manske; Tammy Price-Troska; Steven Ziesmer; Lucy S Hodge; Stephen M Ansell; James R Cerhan; Anne J Novak
Journal:  Leuk Lymphoma       Date:  2014-02-24

Review 5.  Roles of tumor necrosis factor receptor associated factor 3 (TRAF3) and TRAF5 in immune cell functions.

Authors:  Joanne M Hildebrand; Zuoan Yi; Claire M Buchta; Jayakumar Poovassery; Laura L Stunz; Gail A Bishop
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

Review 6.  Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease.

Authors:  Robert C Rickert; Julia Jellusova; Ana V Miletic
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

Review 7.  Roles for TNF-receptor associated factor 3 (TRAF3) in lymphocyte functions.

Authors:  Zuoan Yi; Wai Wai Lin; Laura L Stunz; Gail A Bishop
Journal:  Cytokine Growth Factor Rev       Date:  2013-12-25       Impact factor: 7.638

8.  Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma.

Authors:  Kodandaram Pillarisetti; Gordon Powers; Leopoldo Luistro; Alexander Babich; Eric Baldwin; Yingzhe Li; Xiaochun Zhang; Mark Mendonça; Nate Majewski; Rupesh Nanjunda; Diana Chin; Kathryn Packman; Yusri Elsayed; Ricardo Attar; François Gaudet
Journal:  Blood Adv       Date:  2020-09-22

9.  BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.

Authors:  Jérôme Moreaux; Eric Legouffe; Eric Jourdan; Philippe Quittet; Thierry Rème; Cécile Lugagne; Philippe Moine; Jean-François Rossi; Bernard Klein; Karin Tarte
Journal:  Blood       Date:  2003-12-04       Impact factor: 22.113

10.  BAFF selectively enhances the survival of plasmablasts generated from human memory B cells.

Authors:  Danielle T Avery; Susan L Kalled; Julia I Ellyard; Christine Ambrose; Sarah A Bixler; Marilyn Thien; Robert Brink; Fabienne Mackay; Philip D Hodgkin; Stuart G Tangye
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.